On June 11 and 12, 2026, the RespirERA Institute took part in the 9th edition of the Biomarker Exchange Days (JEBM), held in Avignon and organized by AstraZeneca. This event brought together numerous specialists in medical biology, anatomical pathology, and oncology to discuss recent advances in biomarkers and precision medicine.
Professor Paul Hofman spoke there to present the work and expertise developed within the RespirERA Institute, particularly in the fields of artificial intelligence applied to diagnostics and the identification of new biomarkers of interest in oncology.
RespirERA Institute expertise at JEBM
The Biomarker Exchange Days are a key meeting point for sharing scientific and technological developments that are shaping precision medicine. This approach aims to adapt diagnostic and therapeutic strategies to each patient’s specific biological characteristics.
On this occasion, Professor Paul Hofman took part in discussions alongside Caroline Lacoux and Virginie Lespinet. These meetings made it possible to exchange with the medical community on the perspectives offered by biomarkers in the management of patients with cancer.
Artificial intelligence and anatomical pathology: a diagnostic revolution underway
During his presentation, Professor Paul Hofman presented recent advances combining artificial intelligence and anatomical pathology, a discipline that consists of analyzing tissues and cells in order to identify and characterize diseases.
The use of artificial intelligence algorithms in the analysis of histological images is now opening up new perspectives for pathologists. These tools make it possible in particular to improve the accuracy of certain assessments, to detect characteristics that are difficult to identify with the human eye, and to speed up the analysis of complex data.
This convergence between medical expertise and digital technologies is fully aligned with the RespirERA Institute’s expertise in the use of complex data, integrative pathology, and the development of innovative solutions for respiratory health.
Focus on MTAP: a biomarker of growing interest in oncology
Professor Paul Hofman also presented a current update on MTAP, a biomarker that is generating growing interest in cancer research.
The study of this marker helps to better understand certain mechanisms involved in tumor development and progression. The knowledge gained could, in the long term, make it possible to refine the molecular characterization of certain cancers and to identify new therapeutic opportunities within the framework of personalized medicine.
This topic illustrates the growing importance of biomarkers in improving diagnosis, patient stratification, and guidance toward the most appropriate treatments.
A dynamic in support of precision medicine
The RespirERA Institute’s participation in JEBM 2026 reflects its commitment to diagnostic and therapeutic innovation. By combining expertise in biomarkers, artificial intelligence, and molecular pathology, the institute contributes to the development of increasingly effective precision medicine, benefiting patients with respiratory diseases and thoracic cancers.
FR 
EN 